Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Capon

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Plos One|March 3, 2011
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humansPaola Di Meglio, Antonella Di Cesare, Ute Laggner, et al.
Trials|February 12, 2020
A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trialSuzie Cro, Prakash Patel, Jonathan Barker, et al.
Clinical and Experimental Dermatology|December 17, 2025
Clinical phenotype of 504 pustular psoriasis patients from Europe and Egypt: a multi-center observational studyAlshimaa Mostafa, Ahmed Arafa, Yasser Gohary, et al.
Trials|August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialVictoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
American Journal of Human Genetics|July 31, 2002
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locusColin D Veal, Francesca Capon, Michael H Allen, et al.
Nature Communications|January 30, 2024
Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockadeLuc Francis, Daniel McCluskey, Clarisse Ganier, et al.
The Journal of Investigative Dermatology|November 25, 2011
Allele-specific cytokine responses at the HLA-C locus: implications for psoriasisChristian Hundhausen, Anna Bertoni, Rose K Mak, et al.
The Journal of Investigative Dermatology|August 20, 2013
Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?Alexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
The Journal of Investigative Dermatology|January 30, 2013
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosisAlexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
Science Translational Medicine|October 13, 2017
An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic targetSatveer K Mahil, Marika Catapano, Paola Di Meglio, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Plos One|March 3, 2011
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humansPaola Di Meglio, Antonella Di Cesare, Ute Laggner, et al.
Trials|February 12, 2020
A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trialSuzie Cro, Prakash Patel, Jonathan Barker, et al.
Clinical and Experimental Dermatology|December 17, 2025
Clinical phenotype of 504 pustular psoriasis patients from Europe and Egypt: a multi-center observational studyAlshimaa Mostafa, Ahmed Arafa, Yasser Gohary, et al.
Trials|August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialVictoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
American Journal of Human Genetics|July 31, 2002
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locusColin D Veal, Francesca Capon, Michael H Allen, et al.
Nature Communications|January 30, 2024
Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockadeLuc Francis, Daniel McCluskey, Clarisse Ganier, et al.
The Journal of Investigative Dermatology|November 25, 2011
Allele-specific cytokine responses at the HLA-C locus: implications for psoriasisChristian Hundhausen, Anna Bertoni, Rose K Mak, et al.
The Journal of Investigative Dermatology|August 20, 2013
Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?Alexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
The Journal of Investigative Dermatology|January 30, 2013
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosisAlexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
Science Translational Medicine|October 13, 2017
An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic targetSatveer K Mahil, Marika Catapano, Paola Di Meglio, et al.
Pageof 8